Payam Zarin
Associate Director, Discovery GentiBio
Payam Zarin, PhD, is Associate Director and Research Lead at GentiBio, developing novel strategies to harness regulatory T cells to treat autoimmune and autoinflammatory diseases. His interest in immune tolerance began with internships in the Mathis/Benoist lab at Harvard and Rudensky lab at MSKCC. He earned his PhD in Immunology at the University of Toronto, studying how environmental cues shape hematopoietic stem cell programming. Before GentiBio, Payam was a Banting Fellow at Harvard Medical School, investigating Foxp3-induced genes in peripheral tolerance.
Seminars
Tuesday 24th March 2026
Targeting Autoantigens to Overcome Allogeneic Treg Rejection & Enhance Therapeutic Success
2:15 pm
- Discussing interactions between the immune system and allogeneic Tregs to identify rejection mechanisms
- Investigating opportunities to define and target autoantigens key to allogeneic Treg rejection
- Strategies to remove or modify autoantigens to enhance persistence and prevent treatment rejection
Tuesday 24th March 2026
Roundtable Discussion: Engineering Next-Generation Tregs to Advance Treg Therapeutic Development
1:15 pm
- Investigating engineering Treg cells from CD4+ and iPSC precursors to understand the impact on efficacy
- Examining engineering strategies required to achieve durable Treg stability in vivo for long-term efficacy
- Engineering CAR-Tregs and Allogeneic Tregs for potential therapies of autoimmune and transplant disease
- Growth factor and durability support strategies for long term Treg persistence in patients
